Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H18F3NO3 |
| Molecular Weight | 389.3677 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CO)NC(=O)C1=CC2=CC=CC(OC3=CC=C(C=C3)C(F)(F)F)=C2C=C1
InChI
InChIKey=FJIVCOAHSKDOAC-CYBMUJFWSA-N
InChI=1S/C21H18F3NO3/c1-13(12-26)25-20(27)15-5-10-18-14(11-15)3-2-4-19(18)28-17-8-6-16(7-9-17)21(22,23)24/h2-11,13,26H,12H2,1H3,(H,25,27)/t13-/m1/s1
| Molecular Formula | C21H18F3NO3 |
| Molecular Weight | 389.3677 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:57:49 GMT 2025
by
admin
on
Wed Apr 02 09:57:49 GMT 2025
|
| Record UNII |
7KC2KN2QGK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7KC2KN2QGK
Created by
admin on Wed Apr 02 09:57:49 GMT 2025 , Edited by admin on Wed Apr 02 09:57:49 GMT 2025
|
PRIMARY | |||
|
2506273-81-8
Created by
admin on Wed Apr 02 09:57:49 GMT 2025 , Edited by admin on Wed Apr 02 09:57:49 GMT 2025
|
PRIMARY | |||
|
155214091
Created by
admin on Wed Apr 02 09:57:49 GMT 2025 , Edited by admin on Wed Apr 02 09:57:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
VT3989 potently prevented palmitoylation
IN-VITRO
|
||
|
|
TARGET -> INHIBITOR |
VT3989 potently prevented palmitoylation
IN-VITRO
|
||
|
|
TARGET->WEAK INHIBITOR |
VT3989 potently prevented palmitoylation
IN-VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
VT3989 is a potent and selective inhibitor of the auto-palmitoylation of the transcription factor TEAD, the main partner for the recruitment of the Hippo pathway-regulated transcription co-activator YAP to the chromatin. Auto-palmitoylation of TEAD is essential for TEAD interaction with YAP. Tumors deficient in the NF2 gene function are dependent on YAP function for growth. Therefore, in tumor cells with NF2 gene loss of function mutations, VT3989 is expected to reduce tumor cell proliferation based on its ability to block the interaction of TEAD with YAP and inhibit YAP-TEAD transcriptional activity.
IN-VITRO
|
![Structure of N-[(1R)-2-Hydroxy-1-methylethyl]-5-[4-(trifluoromethyl)phenoxy]-2-naphthalenecarboxamide](/img/9f7a42e3-6d07-4ae7-9df6-35114c827fea.svg "Structure of N-[(1R)-2-Hydroxy-1-methylethyl]-5-[4-(trifluoromethyl)phenoxy]-2-naphthalenecarboxamide")